StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Ultomiris (ravulizumab) by Quarter

Ultomiris (ravulizumab) — Established RoW product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Ultomiris (ravulizumab): $201M in Q2 2026, up 12.3% from a year earlier. That is the highest of the 20 quarters on record here.

Latest, Q2 2026
201
Period ended Jun 30, 2026
Change on a year earlier
+12.3%
179 in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Ultomiris | | 1,314 | | 12 | | 12 | | 719 | | 8 | | 87 | | 42 | | 41 | | 307 | | 14 | | 9 | | 201 | | 12 | | 19”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUltomiris (ravulizumab) — Established RoW product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026201+12.3%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026190+14.5%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025192+11.0%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025200+17.6%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025179+17.8%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025166+16.1%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024173+25.4%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024170+29.8%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024152+38.2%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024143+45.9%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023138+53.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023131+70.1%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023110+52.8%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202398+40.0%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202290+23.3%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202277+37.5%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up ultomiris (ravulizumab)

Cite this data

StockData. (2026). AstraZeneca Ultomiris (ravulizumab) ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-ultomiris-erow

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.